medigraphic.com
Academia Mexicana de Neurología, A.C.

2008, Number 4

<< Back Next >>

Rev Mex Neuroci 2008; 9 (4)

Myasthenia Gravis in a hospital of reference of the west of Mexico

Echeverría-Galindo G, Mardueño-Ibarra MT, González-Jaime JJ, Márquez-Magaña I, Chiquete E, Sandoval-Virgen F, Coronado-Magaña H, Padilla-Martínez JJ, Ruiz-Sandoval JL

Language: Spanish
References: 18
Page: 278-282
PDF size: 52.61 Kb.


ABSTRACT

Introduction: Myasthenia Gravis (MG) is an autoimmune disease of the neuromuscular junction, which has been more studied in high specialty hospitals in our country’s capital city. Objective: To describe the clinical spectrum of MG in a sample of patients from a tertiary referral center of Western México. Material and methods: Consecutive patients were considered if they met diagnostic criteria for MG, seen from 1999 to 2007; considering staging according to the Osserman scale, and information regarding medical or surgical treatment, medical complications and evolution. Results: A total of 43 patients were included, 25 women (58%) and 18 men, with a mean age of 43 years (range: 16 to 47 years). The time from symptoms onset to the moment of diagnosis had a mean of 31 months; nine patients with Osserman I (21%), 14 with IIa (33%), and 19 with IIb (44%). Antibodies against acetylcholine receptor were found in 37% of cases. A total of 27 patients (63%) received prednisone and two (5%) azathrioprine, while thymectomy was performed in 23 patients (53%) with a report of thymus hyperplasia in 52% and thymome in 13%. Global mortality was 16% in a mean follow-up of 60 months. Discussion: MG in our country does not substantially differ from that reported in the medical literature. The seronegative form is highly prevalent probably due to laboratory inconsistencies. There is, on the other hand, an underutilization of the immunesuppressor therapy, and the mortality rate is high, with a tendency to affect to older ages.


REFERENCES

  1. Drachman DB. Myasthenia Gravis. New Engl J Med 1994; 330: 1797-810.

  2. Phillips LH 2nd. The epidemiology of myasthenia gravis. Ann NY Acad Sci 2003; 998: 407-12.

  3. Cacho-Díaz B, Ruano-Calderón LA, Valdez-Ferrer SI, Porras M, García-Ramos G, Cantú-Brito C. Miastenia gravis y sus comorbilidades. Rev Mex Neuroci 2006; 7: 449-50.

  4. Playas-Pérez G, Orozco-Paredes J, Espinoza-Casillas C, Amavisca- Espinoza R, Carrillo-Mora P. Miastenia gravis con poliendocrinopatía autoinmune. Presentación de un caso. Rev Mex Neuroci 2002; 3: 79-81.

  5. Blanco-Gallardo A, Torres-Parada LG, Herrera MF. Timectomía transcervical: alternativa quirúrgica en el tratamiento de la miastenia gravis. Salud en Tabasco 1999; 5: 263-6.

  6. Téllez-Zenteno JF, Morales-Buenrostro LE, Torre-Delgadillo A. Pathogenesis of myasthenia gravis. Rev Invest Clin 2000; 52: 80-5.

  7. Téllez-Zenteno JF, Remes-Troche JM, García-Ramos G, Estañol B, Garduño-Espinoza J. Prognostic factors of thymectomy in patients with myasthenia gravis: a cohort of 132 patients. Eur Neurol 2001; 46: 171-7.

  8. Navarro-Reynoso F, Pérez-Romo A, Green L, Páramo-Arroyo R, Cicero-Sabido R. Resultados de la timectomía máxima en miastenia gravis. Experiencia de 20 años en el Servicio de Neumología y Cirugía de Tórax en el Hospital General de México. Influencia de la timectomía en dosis de piridostigmina y tres variables espirométricas en miastenia gravis. Rev Inst Nal Enf Resp Mex 2006; 19: 252-7.

  9. Remes-Troche JM, Téllez-Zenteno JF, Estañol B, Garduño-Espinoza J, García-Ramos G. Thymectomy in myasthenia gravis: response, complications, and associated conditions. Arch Med Res 2002; 33: 545-51.

  10. Playas-Pérez G, García-Cázarez R, Ramos-Ramíres R. Miastenia gravis familiar. Rev Mex Neuroci 2003; 4: 6.

  11. Guillermo GR, Téllez-Zenteno JF, Weder-Cisneros N, Mimenza A, Estañol B, Remes-Troche JM, Cantu-Brito C. Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand 2004; 109: 217-21.

  12. García-Ramos G, Téllez-Zenteno JF, Zapata-Zúñiga M, Yamamoto- Furusho JK, Ruiz-Morales JA, Villarreal-Garza C, et al. HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. Eur J Neurol 2003; 10: 707-10.

  13. Téllez-Zenteno JF, García-Ramos G, Garduño-Espinoza J, Weder- Cisneros N, Estañol-Vidal B, Domínguez-Fonseca C, et al. Pruebas diagnósticas en miastenia gravis. Conformación de un estándar diagnóstico mediante un método de consenso. Rev Neurol 2001; 33: 825-32.

  14. Osserman KE. Myasthenia Gravis. New York: Grune & Stratton; 1958, p. 80.

  15. Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez L, et al. Anti-Titin antibodies in myasthenia gravis. Tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001; 58: 885-90.

  16. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004; 62: 1945-50.

  17. Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, et al. Antibodies in Myasthenia Gravis and Related Disorders. Ann NY Acad Sci 2003; 998: 324-35.

  18. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7-17.




2020     |     www.medigraphic.com